S2k-Leitlinie: Management der Großgefäßvaskulitiden

Schirmer, Jan Henrik; Aries, Peer; Balzer, K.; Berlit, Peter; Bley, Thorsten Alexander; Buttgereit, Frank; Czihal, Michael; Dechant, Claudia; Dejaco, Christian; Garske, Ulrike; Henes, Joerg; Holle, Julia; Holl‐Ulrich, Konstanze; Lamprecht, Peter; Nölle, Bernhard; Moosig, Frank; Rech, Juergen; Scheuermann, Kathrin; Schmalzing, Marc; Schmidt, Wolfgang A.; Schneider, Matthias; Schulze‐Koops, Hendrik; Venhoff, Nils; Villiger, Peter M.; Witte, Torsten; Zänker, Michael; Hellmich, Bernhard

doi:10.1007/s00393-020-00893-1

Cited by 50 publications

(82 citation statements)

References 255 publications

(348 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Es wird eine entzündliche Beteiligung der Lungenarterien sowie der Hustenrezeptoren im Bronchialbaum angenommen sowie auch die mögliche Präsenz von Granulomen innerhalb der Bronchialwand und des Alveolarepithels diskutiert [10]. schen Gesellschaft für Rheumatologie kann die Diagnose einer GGV neben einer Biopsie auch mittels der Bildgebung (MRA, PET-CT, Duplexsonographie) beurteilt und bestätigt werden [3,11]. In der klinischen Praxis stehen meist initial bereits die Duplexsonographie und wie im vorliegenden Fall ein MRT zur Verfügung.…”

Section: Cough In Times Of Coronavirus Abstractunclassified

See 1 more Smart Citation

Husten in Corona-Zeiten

Ruales¹,

Elkes²,

Miehle³

2021

Z Rheumatol

View full text Add to dashboard Cite

Section: Cough In Times Of Coronavirus Abstractunclassified

“…60 mg) empfohlen. Die Therapie sollte bereits beim bloßen Verdacht auf eine RZA begonnen werden mit einer Zieldosis von 10-15 mg nach 3 Monaten und < 5 mg nach 1 Jahr [3,11]…”

Section: Therapieunclassified

Husten in Corona-Zeiten

Ruales¹,

Elkes²,

Miehle³

2021

Z Rheumatol

View full text Add to dashboard Cite

“…The past decade witnessed appearance of several international and country-specific recommendations on PMR and GCA (Table 3). Besides the specialized societies, such as the European League against Rheumatism (EULAR) and American College of Rheumatology (ACR) [32][33][34], the UK-based societies, namely the British Society for Rheumatology (BSR) and the British Health Professionals in Rheumatology (BHPR), the French Study Group for Large Vessel Vasculitis (Groupe d'étude français des artérites des gros vaisseaux, GEFA) [37], the German Society of Rheumatology (Deutsche Gesellschaft für Rheumatologie, DGRh), the Austrian Society of Rheumatology and Rehabilitation (Österreichische Gesellschaft für Rheumatologie, ÖGR), the Swiss Society of Rheumatology (Schweizerische Gesellschaft für Rheumatologie, SGR) [38], the Italian Society of Reumatology (Società Italiana di Reumatologia, SIR) [39]. The interdisciplinary issue of large-vessel vasculitis management was raised by the guidelines of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF) [40] and the European Headache Federation (EHF) [31].…”

Section: Modern Recommendations On Pmr Gca and Aortic Diseasesmentioning

confidence: 99%

“…The PET was first introduced as an ancillary diagnostic test of vasculitis detection into the PMR management standards in 2020, while the first Italian clinical-practical guidelines were developed [39]. Its prototype -the DGRh/ çGR/SGR guidelines (2018) on PMR management in Germany, Austria and Switzerland -considered the findings of a systemic review including 30 studies on imaging diagnostic tools to detect GCA; however, there were no recommendations on the PET use in clinical practice [38].…”

Section: Recommendations By Eanm/snmmi/pig/ Asnc (2018) On Fdg-pet/ct(a) Use To Treat Large-vessel Vasculitides and Pmrmentioning

confidence: 99%

“…The FDG-PET/CT's accuracy in detecting the articular structure and periarticular tissue inflammations is vitally important for differential PMR diagnostics within a range of late-onset rheumatic diseases associated with infections and tumors [50-54]. However, the 2020 Italian guidelines [39], as well as their prototypes [33,38], opt for the clinical-anamnestic method and clinical judgment: "The real demand for extra tests should be determined by the attending healthcare provider in order to avoid the excessing screenings, which are less beneficial to the patient and incur higher costs" [42].…”

Section: лекції огляди / Lectures Reviewsmentioning

confidence: 99%

See 1 more Smart Citation

Ревматическая Полимиалгия В Клинических Рекомендациях 2018–2020 Гг. Часть II: Диагностика Васкулита

Puzanova¹,

Лызиков²

2021

PJS

View full text Add to dashboard Cite

The issue of improved diagnosis of both rheumatic diseases of the elderly and aortic diseases does not lose its relevance. In terms of aortic aneurysms, dissection and ruptures and their attended pathogenesis, both inflammation and structural wall damages may be detected with imaging methods whose role is vital. A number of international guidelines deal with the management of polymyalgia rheumatica, giant cell arteritis, or aortic aneurysms. Aortitis is associated with up to 40 % of polymyalgia rheumatica’s cases. The clinical suspicion of aortitis is based on the detection of blood pressure and pulse asymmetry, aortic regurgitation murmur, vascular bruits, as well as persistent polymyalgia rheumatica or inflammatory dorsalgia, pelvis or leg pain. In 2020, the positron emission tomography/computed tomography’s use is approved by the Italian Society for Rheumatology for the diagnosis of vasculitis attended by polymyalgia rheumatica at the secondary healthcare level and by the European Headache Federation for the diagnosis of large vessel giant cell arteritis in the neurological practice. A review of the guideline by the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the American Society of Nuclear Cardiology (2018) was performed in terms of positron emission tomography with fluorodesoxyglucose combined with computed tomography (angiography) imaging in large vessel vasculitis and polymyalgia rheumatica. It is further compared with the clinical guidelines, other guidelines by the societies of nuclear medicine and new scientific data. Both procedure and patient’s preparation for examination are decribed. The criteria for assessing vasculitis proposed for either clinical practice or clinical studies are considered, as well as the factors influencing the test results and their interpretation (such as atherosclerosis, diabetes, age, body mass index, glucemia’s and acute phase markers’ levels). The guideline substantiates the benefit of both positron emission tomography’s use and its combination with computed tomography to detect extracranial vasculitis, as well as the value of performing computed tomography-angiography at different stages of the disease. There is a need to strengthen evidence on both standard time of fluorodesoxyglucose exposure and the benefit of combining positron emission tomography with computed tomography-angiography, in particular for detection of vasculitis relapses. Finding a consensus for early test’s performing is needed, as well as its score standardization, ensuring reimbursement and implementation of new imaging techniques for the cranial vessels. In the future, the evidence-based approach to managing vasculitis will be supplemented by teranostics.

show abstract